Eagle Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
EGRX
CUSIP
269796108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 269796108 since 12/18/2024, largest first.

Filer % of Class Filed
Nantahala Capital Management, LLC 13G/A
38.1% 8/14/2025
Event 6/30/2025
Union Square Park Capital Management, LLC 13G/A
11.4% 2/14/2025
Event 12/31/2024
Nantahala Capital Partners Limited Partnership 13G
6.2% 2/19/2025
Event 2/16/2025
J. Goldman & Co LP 13G
5.1% 8/14/2025
Event 6/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 3 12.7 k $8.51 k
2026 Q1 2 12.4 k $4.21 k
2025 Q4 2 12.4 k $8.65 k
2025 Q3 2 12.4 k $33.3 k
2025 Q2 2 12.4 k $35.8 k
2025 Q1 2 12.4 k $12.1 k
2024 Q4 9 79.0 k $38.8 k
2024 Q3 69 8.56 M $31.9 M
2024 Q2 83 12.2 M $68.2 M
2024 Q1 98 11.3 M $59.0 M
2023 Q4 111 10.6 M $55.3 M
2023 Q3 113 10.3 M $163 M
2023 Q2 131 10.8 M $209 M
2023 Q1 156 11.8 M $334 M
2022 Q4 158 12.5 M $366 M
2022 Q3 161 12.8 M $337 M
2022 Q2 166 11.6 M $517 M
2022 Q1 164 11.3 M $557 M
2021 Q4 167 11.3 M $575 M
2021 Q3 153 11.8 M $660 M
2021 Q2 147 12.0 M $516 M
2021 Q1 157 12.2 M $508 M
2020 Q4 170 12.6 M $588 M
2020 Q3 178 12.8 M $542 M
2020 Q2 168 13.2 M $633 M
2020 Q1 174 13.4 M $617 M
2019 Q4 186 13.5 M $812 M
2019 Q3 193 13.3 M $755 M
2019 Q2 198 13.6 M $758 M
2019 Q1 196 14.5 M $731 M
2018 Q4 192 15.2 M $615 M
2018 Q3 206 15.7 M $1.09 B
2018 Q2 193 15.4 M $1.16 B
2018 Q1 185 15.9 M $836 M
2017 Q4 183 16.0 M $853 M
2017 Q3 188 15.9 M $948 M
2017 Q2 187 19.0 M $1.21 B
2017 Q1 156 16.6 M $1.37 B
2016 Q4 161 16.6 M $1.32 B
2016 Q3 150 17.3 M $1.17 B
2016 Q2 131 17.2 M $667 M
2016 Q1 140 15.9 M $643 M
2015 Q4 146 15.0 M $1.33 B
2015 Q3 129 15.0 M $1.11 B
2015 Q2 124 13.4 M $1.08 B
2015 Q1 68 11.7 M $489 M
2014 Q4 28 9.20 M $143 M
2014 Q3 27 2.97 M $37.6 M
2014 Q2 28 1.74 M $25.0 M
2014 Q1 28 1.91 M $24.4 M